TELA Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• TELA Bio Inc TELA.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -51 cents. The mean expectation of five analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -20 cents to -14 cents per share.

• Revenue rose 25.5% to $20.20 million from a year ago; analysts expected $20.68 million.

• TELA Bio Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $9.92 million.

• TELA Bio Inc shares had fallen by 11.3% this quarter and lost 43.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for TELA Bio Inc is $6.00, about 71.3% above its last closing price of $1.72

This summary was machine generated from LSEG data August 11 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)